Home ➤ Life Science ➤ Healthcare ➤ Biologics Market
Biologics Market
Published date: Aug 2025 • Formats:
[email protected] +1 718 874 1545
Request Sample Schedule a Call

Table of Contents

Biologics MarketBiologics Market By Product Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics, Others), By Manufacturing (Outsourced, In-house), By Application (Oncology, Immunology, Infectiuos Disease, Cardiovascular Disorders, Others), By Source (Microbial, Mammalian, Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: Aug 2025
  • Report ID: 64874
  • Number of Pages: 297
  • Format:
Fact Checked
Biologics Market https://market.us/report/biologics-market/
Cite this Research
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
      • 1.8. Industry Voices
    • 2. Global Market Overview
      • 2.1. Global Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Drivers
        • 2.2.2. Restraints
        • 2.2.3. Opportunities
        • 2.2.4. Key Biologics Market Trends
      • 2.3. Technology Landscape
      • 2.4. Regulatory Framework
      • 2.5. Sustainability and ESG (Environmental, Social, Governance)
      • 2.6. Opportunity Map Analysis
      • 2.7. Opportunity Orbits
      • 2.8. PESTLE Analysis
      • 2.9. PORTER’S Five Force Analysis
      • 2.10. Drivers & Restraints Impact Analysis
      • 2.11. Value Chain Analysis
        • 2.11.1. List of Raw Materials Suppliers
        • 2.11.2. List of Biologics Manufacturers
        • 2.11.3. List of Dealer/Distributors
      • 2.12. Regional Market Share and BPS Analysis
      • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Global Biologics Market Analysis and Forecast, By Segment, 2020-2034
      • 3.1. Key Findings
      • 3.2. Global Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 3.3. Global Biologics Market Attractiveness Analysis, By Product Type
        • 3.3.1. Monoclonal Antibodies
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
            • 3.3.1.2.1. MABs by Application
              • 3.3.1.2.1.1. Diagnostic
                • 3.3.1.2.1.1.1. Biochemical Analysis
                • 3.3.1.2.1.1.2. Diagnostic Imaging
              • 3.3.1.2.1.2. Therapeutic
                • 3.3.1.2.1.2.1. Direct MAB Agents
                • 3.3.1.2.1.2.2. Targeting MAB Agents
            • 3.3.1.2.1.3. Protein Purification
            • 3.3.1.2.1.4. Others
          • 3.3.1.2.2. MABs by Type
            • 3.3.1.2.2.1. Murine
            • 3.3.1.2.2.2. Chimeric
            • 3.3.1.2.2.3. Humanized
            • 3.3.1.2.2.4. Human
            • 3.3.1.2.2.5. Others
        • 3.3.2. Vaccines
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. Recombinant Proteins
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. Antisense & RNAi Therapeutics
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Others
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
      • 3.4. Global Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 3.5. Global Biologics Market Attractiveness Analysis, By Manufacturing
        • 3.5.1. Outsourced
          • 3.5.1.1. Insights
          • 3.5.1.2. Key Takeaways
        • 3.5.2. In-House
          • 3.5.2.1. Insights
          • 3.5.2.2. Key Takeaways
      • 3.6. Global Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 3.7. Global Biologics Market Attractiveness Analysis, By Application
        • 3.7.1. Oncology
          • 3.7.1.1. Insights
          • 3.7.1.2. Key Takeaways
        • 3.7.2. Immunology
          • 3.7.2.1. Insights
          • 3.7.2.2. Key Takeaways
        • 3.7.3. Infectious Disease
          • 3.7.3.1. Insights
          • 3.7.3.2. Key Takeaways
        • 3.7.4. Cardiovascular Disorders
          • 3.7.4.1. Insights
          • 3.7.4.2. Key Takeaways
        • 3.7.5. Others
          • 3.7.5.1. Insights
          • 3.7.5.2. Key Takeaways
      • 3.8. Global Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 3.9. Global Biologics Market Attractiveness Analysis, By Source
        • 3.9.1. Microbial
          • 3.9.1.1. Insights
          • 3.9.1.2. Key Takeaways
        • 3.9.2. Mammalian
          • 3.9.2.1. Insights
          • 3.9.2.2. Key Takeaways
        • 3.9.3. Others
          • 3.9.3.1. Insights
          • 3.9.3.2. Key Takeaways
    • 4. Global Biologics Market Analysis and Forecast, By Region, 2020-2034
      • 4.1. Key Findings
      • 4.2. Global Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
        • 4.2.1. North America
          • 4.2.1.1. Regional Insights
        • 4.2.2. Europe
          • 4.2.2.1. Regional Insights
        • 4.2.3. Asia Pacific
          • 4.2.3.1. Regional Insights
        • 4.2.4. Latin America
          • 4.2.4.1. Regional Insights
        • 4.2.5. Middle East & Africa
          • 4.2.5.1. Regional Insights
      • 4.3. Global Biologics Market Attractiveness Analysis, By Region
    • 5. North America Biologics Market Analysis and Forecast, 2020-2034
      • 5.1. Key Findings
      • 5.2. North America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 5.3. North America Biologics Market Attractiveness Analysis, By Product Type
      • 5.4. North America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 5.5. North America Biologics Market Attractiveness Analysis, By Manufacturing
      • 5.6. North America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 5.7. North America Biologics Market Attractiveness Analysis, By Application
      • 5.8. North America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 5.9. North America Biologics Market Attractiveness Analysis, By Source
      • 5.10. North America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 5.11. North America Biologics Market Attractiveness Analysis, By Country
        • 5.11.1. The US
        • 5.11.2. Canada
    • 6. Europe Biologics Market Analysis and Forecast, 2020-2034
      • 6.1. Key Findings
      • 6.2. Europe Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 6.3. Europe Biologics Market Attractiveness Analysis, By Product Type
      • 6.4. Europe Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 6.5. Europe Biologics Market Attractiveness Analysis, By Manufacturing
      • 6.6. Europe Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 6.7. Europe Biologics Market Attractiveness Analysis, By Application
      • 6.8. Europe Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 6.9. Europe Biologics Market Attractiveness Analysis, By Source
      • 6.10. Europe Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 6.11. Europe Biologics Market Attractiveness Analysis, By Country
        • 6.11.1. Germany
        • 6.11.2. The UK
        • 6.11.3. France
        • 6.11.4. Spain
        • 6.11.5. Italy
        • 6.11.6. Russia
        • 6.11.7. Netherland
        • 6.11.8. Rest of Europe
    • 7. Asia Pacific Biologics Market Analysis and Forecast, 2020-2034
      • 7.1. Key Findings
      • 7.2. Asia Pacific Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 7.3. Asia Pacific Biologics Market Attractiveness Analysis, By Product Type
      • 7.4. Asia Pacific Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 7.5. Asia Pacific Biologics Market Attractiveness Analysis, By Manufacturing
      • 7.6. Asia Pacific Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 7.7. Asia Pacific Biologics Market Attractiveness Analysis, By Application
      • 7.8. Asia Pacific Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 7.9. Asia Pacific Biologics Market Attractiveness Analysis, By Source
      • 7.10. Asia Pacific Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 7.11. Asia Pacific Biologics Market Attractiveness Analysis, By Country
        • 7.11.1. China
        • 7.11.2. Japan
        • 7.11.3. South Korea
        • 7.11.4. India
        • 7.11.5. Australia
        • 7.11.6. New Zealand
        • 7.11.7. Singapore
        • 7.11.8. Thailand
        • 7.11.9. Vietnam
        • 7.11.10. Rest of Asia Pacific
    • 8. Latin America Biologics Market Analysis and Forecast, 2020-2034
      • 8.1. Key Findings
      • 8.2. Latin America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 8.3. Latin America Biologics Market Attractiveness Analysis, By Product Type
      • 8.4. Latin America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 8.5. Latin America Biologics Market Attractiveness Analysis, By Manufacturing
      • 8.6. Latin America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 8.7. Latin America Biologics Market Attractiveness Analysis, By Application
      • 8.8. Latin America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 8.9. Latin America Biologics Market Attractiveness Analysis, By Source
      • 8.10. Latin America Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 8.11. Latin America Biologics Market Attractiveness Analysis, By Country
        • 8.11.1. Brazil
        • 8.11.2. Mexico
        • 8.11.3. Rest of Latin America
    • 9. Middle East & Africa Biologics Market Analysis and Forecast, 2020-2034
      • 9.1. Key Findings
      • 9.2. Middle East & Africa Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 9.3. Middle East & Africa Biologics Market Attractiveness Analysis, By Product Type
      • 9.4. Middle East & Africa Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Manufacturing, 2020-2034
      • 9.5. Middle East & Africa Biologics Market Attractiveness Analysis, By Manufacturing
      • 9.6. Middle East & Africa Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 9.7. Middle East & Africa Biologics Market Attractiveness Analysis, By Application
      • 9.8. Middle East & Africa Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Source, 2020-2034
      • 9.9. Middle East & Africa Biologics Market Attractiveness Analysis, By Source
      • 9.10. Middle East & Africa Biologics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 9.11. Middle East & Africa Biologics Market Attractiveness Analysis, By Country
        • 9.11.1. South Africa
        • 9.11.2. Saudi Arabia
        • 9.11.3. UAE
        • 9.11.4. Rest of Middle East & Africa
    • 10. Competitive Landscape & Company Profiles
      • 10.1. Market Competition Scenario Analysis, By Company
        • 10.1.1. Key Takeaways
      • 10.2. Overview of Major Market Players
      • 10.3. Competitor Landscape
      • 10.4. Strategic Mapping
      • 10.5. Company Life Cycle Analysis
      • 10.6. Company Market Share Analysis
      • 10.7. Company Profiles
        • 10.7.1. Sanofi
          • 10.7.1.1. Company Details
          • 10.7.1.2. Business Overview
          • 10.7.1.3. Product Portfolio
          • 10.7.1.4. Financial Insights
          • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.1.6. SWOT Analysis
          • 10.7.1.7. Geographic Footprint
        • 10.7.2. Samsung Biologics
          • 10.7.2.1. Company Details
          • 10.7.2.2. Business Overview
          • 10.7.2.3. Product Portfolio
          • 10.7.2.4. Financial Insights
          • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.2.6. SWOT Analysis
          • 10.7.2.7. Geographic Footprint
        • 10.7.3. Novo Nordisk A/S
          • 10.7.3.1. Company Details
          • 10.7.3.2. Business Overview
          • 10.7.3.3. Product Portfolio
          • 10.7.3.4. Financial Insights
          • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.3.6. SWOT Analysis
          • 10.7.3.7. Geographic Footprint
        • 10.7.4. Johnson & Johnson Services, Inc
          • 10.7.4.1. Company Details
          • 10.7.4.2. Business Overview
          • 10.7.4.3. Product Portfolio
          • 10.7.4.4. Financial Insights
          • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.4.6. SWOT Analysis
          • 10.7.4.7. Geographic Footprint
        • 10.7.5. F. Hoffmann La-Roche Ltd
          • 10.7.5.1. Company Details
          • 10.7.5.2. Business Overview
          • 10.7.5.3. Product Portfolio
          • 10.7.5.4. Financial Insights
          • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.5.6. SWOT Analysis
          • 10.7.5.7. Geographic Footprint
        • 10.7.6. Eli Lilly and Company
          • 10.7.6.1. Company Details
          • 10.7.6.2. Business Overview
          • 10.7.6.3. Product Portfolio
          • 10.7.6.4. Financial Insights
          • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.6.6. SWOT Analysis
          • 10.7.6.7. Geographic Footprint
        • 10.7.7. Celltrion Healthcare Co., Ltd
          • 10.7.7.1. Company Details
          • 10.7.7.2. Business Overview
          • 10.7.7.3. Product Portfolio
          • 10.7.7.4. Financial Insights
          • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.7.6. SWOT Analysis
          • 10.7.7.7. Geographic Footprint
        • 10.7.8. Bristol-Myers Squibb Company
          • 10.7.8.1. Company Details
          • 10.7.8.2. Business Overview
          • 10.7.8.3. Product Portfolio
          • 10.7.8.4. Financial Insights
          • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.8.6. SWOT Analysis
          • 10.7.8.7. Geographic Footprint
        • 10.7.9. Amgen Inc
          • 10.7.9.1. Company Details
          • 10.7.9.2. Business Overview
          • 10.7.9.3. Product Portfolio
          • 10.7.9.4. Financial Insights
          • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.9.6. SWOT Analysis
          • 10.7.9.7. Geographic Footprint
        • 10.7.10. AbbVie Inc
          • 10.7.10.1. Company Details
          • 10.7.10.2. Business Overview
          • 10.7.10.3. Product Portfolio
          • 10.7.10.4. Financial Insights
          • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.10.6. SWOT Analysis
          • 10.7.10.7. Geographic Footprint
    • 11. Methodology and Data Source
      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer
    • List of Tables
      • Table 1. Global Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 2. Global Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 3. Global Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 4. Global Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 5. Global Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 6. Global Biologics Market Value (US$ Mn), By Region, 2020-2034
      • Table 7. North America Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 8. North America Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 9. North America Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 10. North America Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 11. North America Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 12. North America Biologics Market Value (US$ Mn), By Country, 2020–2034
      • Table 13. The US Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 14. The US Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 15. The US Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 16. The US Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 17. The US Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 18. Canada Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 19. Canada Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 20. Canada Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 21. Canada Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 22. Canada Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 23. Europe Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 24. Europe Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 25. Europe Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 26. Europe Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 27. Europe Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 28. Europe Biologics Market Value (US$ Mn), By Country, 2020–2034
      • Table 29. Germany Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 30. Germany Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 31. Germany Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 32. Germany Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 33. Germany Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 34. France Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 35. France Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 36. France Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 37. France Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 38. France Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 39. UK Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 40. UK Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 41. UK Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 42. UK Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 43. UK Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 44. Spain Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 45. Spain Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 46. Spain Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 47. Spain Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 48. Spain Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 49. Italy Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 50. Italy Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 51. Italy Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 52. Italy Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 53. Italy Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 54. Russia Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 55. Russia Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 56. Russia Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 57. Russia Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 58. Russia Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 59. Netherlands Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 60. Netherlands Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 61. Netherlands Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 62. Netherlands Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 63. Netherlands Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 64. Rest of Europe Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 65. Rest of Europe Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 66. Rest of Europe Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 67. Rest of Europe Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 68. Rest of Europe Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 69. Asia Pacific Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 70. Asia Pacific Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 71. Asia Pacific Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 72. Asia Pacific Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 73. Asia Pacific Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 74. Asia Pacific Biologics Market Value (US$ Mn), By Country, 2020–2034
      • Table 75. China Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 76. China Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 77. China Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 78. China Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 79. China Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 80. Japan Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 81. Japan Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 82. Japan Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 83. Japan Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 84. Japan Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 85. South Korea Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 86. South Korea Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 87. South Korea Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 88. South Korea Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 89. South Korea Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 90. India Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 91. India Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 92. India Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 93. India Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 94. India Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 95. Australia Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 96. Australia Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 97. Australia Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 98. Australia Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 99. Australia Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 100. New Zealand Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 101. New Zealand Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 102. New Zealand Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 103. New Zealand Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 104. New Zealand Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 105. Singapore Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 106. Singapore Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 107. Singapore Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 108. Singapore Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 109. Singapore Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 110. Thailand Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 111. Thailand Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 112. Thailand Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 113. Thailand Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 114. Thailand Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 115. Vietnam Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 116. Vietnam Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 117. Vietnam Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 118. Vietnam Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 119. Vietnam Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 120. Rest of Asia Pacific Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 121. Rest of Asia Pacific Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 122. Rest of Asia Pacific Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 123. Rest of Asia Pacific Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 124. Rest of Asia Pacific Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 125. Latin America Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 126. Latin America Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 127. Latin America Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 128. Latin America Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 129. Latin America Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 130. Latin America Biologics Market Value (US$ Mn), By Country, 2020–2034
      • Table 131. Brazil Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 132. Brazil Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 133. Brazil Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 134. Brazil Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 135. Brazil Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 136. Mexico Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 137. Mexico Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 138. Mexico Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 139. Mexico Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 140. Mexico Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 141. Rest of Latin America Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 142. Rest of Latin America Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 143. Rest of Latin America Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 144. Rest of Latin America Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 145. Rest of Latin America Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 146. Middle East & Africa Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 147. Middle East & Africa Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 148. Middle East & Africa Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 149. Middle East & Africa Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 150. Middle East & Africa Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 151. Middle East & Africa Biologics Market Value (US$ Mn), By Country, 2020–2034
      • Table 152. South Africa Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 153. South Africa Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 154. South Africa Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 155. South Africa Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 156. South Africa Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 157. Saudi Arabia Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 158. Saudi Arabia Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 159. Saudi Arabia Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 160. Saudi Arabia Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 161. Saudi Arabia Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 162. UAE Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 163. UAE Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 164. UAE Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 165. UAE Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 166. UAE Biologics Market Value (US$ Mn), By Source, 2020–2034
      • Table 167. Rest of Middle East & Africa Biologics Market Value (US$ Mn), By Product Type, 2020–2034
      • Table 168. Rest of Middle East & Africa Biologics Market Value (US$ Mn), By Monoclonal Antibodies, 2020–2034
      • Table 169. Rest of Middle East & Africa Biologics Market Value (US$ Mn), By Manufacturing, 2020–2034
      • Table 170. Rest of Middle East & Africa Biologics Market Value (US$ Mn), By Application, 2020–2034
      • Table 171. Rest of Middle East & Africa Biologics Market Value (US$ Mn), By Source, 2020–2034
    • List of Figures
      • Figure 1. Global Biologics Market Snapshot: Market Value (US$ Mn), 2020-2034
      • Figure 2. Opportunity Map
      • Figure 3. Opportunity Orbit
      • Figure 4. Regional Market Share and BPS Analysis in Biologics Market
      • Figure 5. Global Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 6. Global Biologics Market Attractiveness Analysis, By Product Type
      • Figure 7. Global Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 8. Global Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 9. Global Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 10. Global Biologics Market Attractiveness Analysis, By Application
      • Figure 11. Global Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 12. Global Biologics Market Attractiveness Analysis, By Source
      • Figure 13. Global Biologics Market Analysis, By Region, 2020, 2024 and 2034
      • Figure 14. Global Biologics Market Attractiveness Analysis, By Region
      • Figure 15. North America Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 16. North America Biologics Market Attractiveness Analysis, By Product Type
      • Figure 17. North America Biologics Market (US$ Mn), by Monoclonal Antibodies, 2020-2034
      • Figure 18. North America Biologics Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 19. North America Biologics Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 20. North America Biologics Market (US$ Mn), by Antisense & RNAi Therapeutics, 2020-2034
      • Figure 21. North America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 22. North America Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 23. North America Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 24. North America Biologics Market (US$ Mn), by Outsourced, 2020-2034
      • Figure 25. North America Biologics Market (US$ Mn), by In-House, 2020-2034
      • Figure 26. North America Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 27. North America Biologics Market Attractiveness Analysis, By Application
      • Figure 28. North America Biologics Market (US$ Mn), by Oncology, 2020-2034
      • Figure 29. North America Biologics Market (US$ Mn), by Immunology, 2020-2034
      • Figure 30. North America Biologics Market (US$ Mn), by Infectious Disease, 2020-2034
      • Figure 31. North America Biologics Market (US$ Mn), by Cardiovascular Disorders, 2020-2034
      • Figure 32. North America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 33. North America Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 34. North America Biologics Market Attractiveness Analysis, By Source
      • Figure 35. North America Biologics Market (US$ Mn), by Microbial, 2020-2034
      • Figure 36. North America Biologics Market (US$ Mn), by Mammalian, 2020-2034
      • Figure 37. North America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 38. North America Biologics Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 39. North America Biologics Market Attractiveness Analysis, By Country
      • Figure 40. Europe Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 41. Europe Biologics Market Attractiveness Analysis, By Product Type
      • Figure 42. Europe Biologics Market (US$ Mn), by Monoclonal Antibodies, 2020-2034
      • Figure 43. Europe Biologics Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 44. Europe Biologics Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 45. Europe Biologics Market (US$ Mn), by Antisense & RNAi Therapeutics, 2020-2034
      • Figure 46. Europe Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 47. Europe Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 48. Europe Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 49. Europe Biologics Market (US$ Mn), by Outsourced, 2020-2034
      • Figure 50. Europe Biologics Market (US$ Mn), by In-House, 2020-2034
      • Figure 51. Europe Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 52. Europe Biologics Market Attractiveness Analysis, By Application
      • Figure 53. Europe Biologics Market (US$ Mn), by Oncology, 2020-2034
      • Figure 54. Europe Biologics Market (US$ Mn), by Immunology, 2020-2034
      • Figure 55. Europe Biologics Market (US$ Mn), by Infectious Disease, 2020-2034
      • Figure 56. Europe Biologics Market (US$ Mn), by Cardiovascular Disorders, 2020-2034
      • Figure 57. Europe Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 58. Europe Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 59. Europe Biologics Market Attractiveness Analysis, By Source
      • Figure 60. Europe Biologics Market (US$ Mn), by Microbial, 2020-2034
      • Figure 61. Europe Biologics Market (US$ Mn), by Mammalian, 2020-2034
      • Figure 62. Europe Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 63. Europe Biologics Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 64. Europe Biologics Market Attractiveness Analysis, By Country
      • Figure 65. Asia Pacific Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 66. Asia Pacific Biologics Market Attractiveness Analysis, By Product Type
      • Figure 67. Asia Pacific Biologics Market (US$ Mn), by Monoclonal Antibodies, 2020-2034
      • Figure 68. Asia Pacific Biologics Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 69. Asia Pacific Biologics Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 70. Asia Pacific Biologics Market (US$ Mn), by Antisense & RNAi Therapeutics, 2020-2034
      • Figure 71. Asia Pacific Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 72. Asia Pacific Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 73. Asia Pacific Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 74. Asia Pacific Biologics Market (US$ Mn), by Outsourced, 2020-2034
      • Figure 75. Asia Pacific Biologics Market (US$ Mn), by In-House, 2020-2034
      • Figure 76. Asia Pacific Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 77. Asia Pacific Biologics Market Attractiveness Analysis, By Application
      • Figure 78. Asia Pacific Biologics Market (US$ Mn), by Oncology, 2020-2034
      • Figure 79. Asia Pacific Biologics Market (US$ Mn), by Immunology, 2020-2034
      • Figure 80. Asia Pacific Biologics Market (US$ Mn), by Infectious Disease, 2020-2034
      • Figure 81. Asia Pacific Biologics Market (US$ Mn), by Cardiovascular Disorders, 2020-2034
      • Figure 82. Asia Pacific Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 83. Asia Pacific Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 84. Asia Pacific Biologics Market Attractiveness Analysis, By Source
      • Figure 85. Asia Pacific Biologics Market (US$ Mn), by Microbial, 2020-2034
      • Figure 86. Asia Pacific Biologics Market (US$ Mn), by Mammalian, 2020-2034
      • Figure 87. Asia Pacific Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 88. Asia Pacific Biologics Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 89. Asia Pacific Biologics Market Attractiveness Analysis, By Country
      • Figure 90. Latin America Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 91. Latin America Biologics Market Attractiveness Analysis, By Product Type
      • Figure 92. Latin America Biologics Market (US$ Mn), by Monoclonal Antibodies, 2020-2034
      • Figure 93. Latin America Biologics Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 94. Latin America Biologics Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 95. Latin America Biologics Market (US$ Mn), by Antisense & RNAi Therapeutics, 2020-2034
      • Figure 96. Latin America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 97. Latin America Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 98. Latin America Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 99. Latin America Biologics Market (US$ Mn), by Outsourced, 2020-2034
      • Figure 100. Latin America Biologics Market (US$ Mn), by In-House, 2020-2034
      • Figure 101. Latin America Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 102. Latin America Biologics Market Attractiveness Analysis, By Application
      • Figure 103. Latin America Biologics Market (US$ Mn), by Oncology, 2020-2034
      • Figure 104. Latin America Biologics Market (US$ Mn), by Immunology, 2020-2034
      • Figure 105. Latin America Biologics Market (US$ Mn), by Infectious Disease, 2020-2034
      • Figure 106. Latin America Biologics Market (US$ Mn), by Cardiovascular Disorders, 2020-2034
      • Figure 107. Latin America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 108. Latin America Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 109. Latin America Biologics Market Attractiveness Analysis, By Source
      • Figure 110. Latin America Biologics Market (US$ Mn), by Microbial, 2020-2034
      • Figure 111. Latin America Biologics Market (US$ Mn), by Mammalian, 2020-2034
      • Figure 112. Latin America Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 113. Latin America Biologics Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 114. Latin America Biologics Market Attractiveness Analysis, By Country
      • Figure 115. Middle East & Africa Biologics Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 116. Middle East & Africa Biologics Market Attractiveness Analysis, By Product Type
      • Figure 117. Middle East & Africa Biologics Market (US$ Mn), by Monoclonal Antibodies, 2020-2034
      • Figure 118. Middle East & Africa Biologics Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 119. Middle East & Africa Biologics Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 120. Middle East & Africa Biologics Market (US$ Mn), by Antisense & RNAi Therapeutics, 2020-2034
      • Figure 121. Middle East & Africa Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 122. Middle East & Africa Biologics Market Analysis, By Manufacturing, 2020, 2024 and 2034
      • Figure 123. Middle East & Africa Biologics Market Attractiveness Analysis, By Manufacturing
      • Figure 124. Middle East & Africa Biologics Market (US$ Mn), by Outsourced, 2020-2034
      • Figure 125. Middle East & Africa Biologics Market (US$ Mn), by In-House, 2020-2034
      • Figure 126. Middle East & Africa Biologics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 127. Middle East & Africa Biologics Market Attractiveness Analysis, By Application
      • Figure 128. Middle East & Africa Biologics Market (US$ Mn), by Oncology, 2020-2034
      • Figure 129. Middle East & Africa Biologics Market (US$ Mn), by Immunology, 2020-2034
      • Figure 130. Middle East & Africa Biologics Market (US$ Mn), by Infectious Disease, 2020-2034
      • Figure 131. Middle East & Africa Biologics Market (US$ Mn), by Cardiovascular Disorders, 2020-2034
      • Figure 132. Middle East & Africa Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 133. Middle East & Africa Biologics Market Analysis, By Source, 2020, 2024 and 2034
      • Figure 134. Middle East & Africa Biologics Market Attractiveness Analysis, By Source
      • Figure 135. Middle East & Africa Biologics Market (US$ Mn), by Microbial, 2020-2034
      • Figure 136. Middle East & Africa Biologics Market (US$ Mn), by Mammalian, 2020-2034
      • Figure 137. Middle East & Africa Biologics Market (US$ Mn), by Others, 2020-2034
      • Figure 138. Middle East & Africa Biologics Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 139. Middle East & Africa Biologics Market Attractiveness Analysis, By Country
    • Sanofi
    • Samsung Biologics
    • Novo Nordisk A/S
    • Johnson & Johnson Services, Inc
    • Hoffmann La-Roche Ltd
    • Eli Lilly and Company
    • Celltrion Healthcare Co., Ltd
    • Bristol-Myers Squibb Company
    • Amgen Inc
    • AbbVie Inc
Biologics Market
Biologics Market
Published date: Aug 2025
add_shopping_cartBuy Now get_appDownload Sample

Related Reports

Biologics Market
  • 64874
  • Aug 2025
    • ★★★★★
      ★★★★★
Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo

Our Clients

✖
Request a Sample Report
We'll get back to you as quickly as possible

✖
Request a Sample Report
We'll get back to you as quickly as possible

Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options